Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) receptor , is exhibiting promising results in preliminary patient trials . Recent research https://socialistener.com/story6858319/retatrutide-emerging-investigations-and-projected-therapeutic-roles